🧾 What This Document Is

This is an SEC Form 8-K filing that announces a major deal. It includes the full, legally binding "Agreement and Plan of Merger" between Apellis Pharmaceuticals (the target) and Biogen (the buyer). In simple terms, this document is the detailed rulebook for how Biogen will buy Apellis. It’s not a press release—it’s the actual contract that lawyers and regulators will look at.

👉 Why it matters: This filing is the official, step-by-step plan. It locks both companies into specific promises and deadlines, and it shows Apellis shareholders exactly what they're being offered.

🏢 What The Company Does

Apellis Pharmaceuticals, Inc. (ticker: APLS) is a biopharmaceutical company. They focus on developing complement inhibitors, which are drugs that target a specific part of the immune system. Their work is particularly relevant for treating diseases like geographic atrophy (a form of age-related macular degeneration) and certain rare kidney disorders.

👉 In simple terms: Imagine your immune system as a security guard. Sometimes, this guard gets overactive and attacks your own body. Apellis makes drugs that are like a "volume knob," trying to dial down that overactivity in specific diseases.

🤝 The Deal: Price & Structure

This isn't a simple all-cash buyout. The deal has two parts, creating a "base + potential bonus" structure for shareholders.

• 💵 Cash Component: $41.00 per share of Apellis common stock, paid in cash.
• 🎫 Contingent Value Right (CVR): One CVR per share. This is a separate, tradeable right that pays out additional cash if Apellis hits specific future sales milestones with its drugs. The maximum total potential value from the CVRs is $4.00 per share.

👉 Why it matters: Biogen is paying a guaranteed $41 upfront, but is also tying part of the final price to Apellis's future commercial success. This structure lets Biogen pay a lower certain price while still giving Apellis shareholders a chance to benefit if the drugs do very well.

🚀 Key Moves: The Two-Step Process

The acquisition will happen in a specific, two-step sequence designed for speed and certainty.

1. The Tender Offer: Biogen will immediately launch a cash offer to buy all Apellis shares at the price above. Apellis's board has unanimously recommended that shareholders accept this offer and tender their shares.
2. The Backside Merger: Once enough shares are tendered (likely over 50%), Biogen will use a special Delaware law (Section 251(h)) to automatically merge its subsidiary with Apellis. This "back-end" merger will happen quickly, without needing a separate shareholder vote. Any shares not tendered in the first step will be "squeezed out" and automatically converted into the same $41.00 + CVR consideration.

👉 Why it matters: This "tender-back-end merger" combo is a common, efficient playbook for takeovers. It avoids a lengthy shareholder meeting process, getting cash to sellers faster.

📦 Financial Position: Employee & Warrant Treatment

The agreement has detailed rules for what happens to employee stock options, RSUs, and company warrants.

• Stock Options & RSUs: Some will be paid out in cash immediately ("cash-out"). Others, especially for employees who stay, will convert into new rights that keep their original vesting schedule but will pay out in cash + CVRs later.
• Company Warrants: All outstanding warrants will be deemed "exercised" in a cashless manner right before the merger, turning into shares that will then receive the merger consideration.

💸 Cash Flow Story: Where the Money Goes

The filing outlines the flow of billions of dollars.

1. Biogen's Commitment: Biogen must deposit all funds needed to buy the tendered shares into a payment fund managed by a Paying Agent (Equiniti Trust Company).
2. Payment Timeline: Once shares are accepted for purchase, shareholders must be paid within three business days.
3. CVR Obligation: Biogen's obligation for the potential CVR payments is separate. The money for those future payments will be deposited only if and when the milestones are achieved.

🔮 What's Next: Timeline & Conditions

The deal is not final yet; certain "conditions to closing" must be met.

• Tender Offer Period: The offer will expire around 20 business days after it starts, but can be extended.
• Key Conditions: The deal can be called off if, for example, Apellis's financials turn out to be significantly worse than represented, or if a court blocks the merger. The deal does not require a vote of Apellis stockholders.
• Expected Closing: The companies aim to close the deal "as soon as practicable" after the tender offer closes, potentially on the same day.

⚖️ Big Picture: Strengths & Risks

👍 Strengths of the Deal:

• Premium & Certainty: The $41 cash offer provides immediate, certain value to shareholders.
• Upside Potential: The CVRs offer a continued stake in the future success of Apellis's key drugs.
• Strong Support: The Apellis board unanimously recommends the deal, and major shareholders have signed "Tender and Support Agreements" to vote yes.

⚠️ Risks & Considerations:

• CVR Uncertainty: The extra $4/share from CVRs is not guaranteed. It depends entirely on future net sales of specific drugs, which is inherently uncertain.
• Deal Completion Risk: If the deal falls apart, Apellis's stock price could drop significantly.
• Opportunity Cost: By accepting a fixed price, shareholders give up all future upside in Apellis beyond the CVR milestones.

🧠 The Analogy

Think of this like selling your house. Biogen is offering $410,000 in cash at closing (the tender offer). But they're also giving you a special coupon (the CVR) that says: "If the new community center being built nearby is a huge success (the sales milestones), we'll pay you an additional $40,000 in two years." You get a great, sure price today, but also a little piece of the potential future neighborhood boom.

📇 Key Contacts & People

The agreement lists the primary contacts for the companies involved:

• For Apellis Pharmaceuticals, Inc.:

  • Cedric Francois, M.D. - Chief Executive Officer & Co-Founder
  • Aron M. Howbert, J.D. - Chief Business Officer & General Counsel
  • Contact: Not specified in this document.

• For Biogen Inc. and Aspen Purchaser Sub, Inc.:

  • Christopher A. Viehbacher - Chief Executive Officer
  • Brian J. Koff - Chief Business Officer
  • Contact: Not specified in this document.

(Note: The specific legal notices section (Article X) would contain formal mailing addresses for official notices, but the key business contacts are the executives listed above.)

🧩 Final Takeaway

Apellis is being acquired by Biogen in a two-part deal: a guaranteed $41 per share in cash now, plus the chance for up to $4 more per share later if its drugs hit sales targets. The process is designed for a quick, certain payout for shareholders who tender their shares, with the full deal mechanics now legally locked in by this filed agreement.